The U.S. FDA warned against the increased risk of death posed by the intravenous antibiotic tigecycline by adding a boxed notice to the label stating that the drug "should be reserved for use in situations when alternative treatments are not suitable." The new warning came after the FDA analyzed data from 10 clinical trials and found the risk of death was 2.5% for patients receiving tigecycline, compared with 1.8% for those on other antibiotics.

Related Summaries